All-case post-marketing surveillance of delamanid for treating multidrug-resistant pulmonary tuberculosis in Japan

20260 citationsJournal Articlehybrid Open Access

Authors

Toru Mori · Japan Anti Tuberculosis Association

Kazunari Tsuyuguchi · National Kinki Chuo Hospital for Chest Disease

Takefumi Saito · Ibarakihigashi National Hospital

Yuka Sasaki · Tokyo National Hospital

Eriko Shigeto · Higashihiroshima Medical Center

Hideaki Nagai · Tokyo National Hospital

Satoshi Komaniwa

Abstract

This surveillance showed the effectiveness of ≥6 months of delamanid treatment among patients with MDR-TB in real-world settings in Japan, with no new safety issues identified.

Topics & Keywords

Tuberculosis Research and Epidemiology Pharmaceutical Quality and Counterfeiting Mycobacterium research and diagnosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Respiratory Investigation

Volume 64, Issue 2, pp. 101363-101363

DOI: 10.1016/j.resinv.2025.101363

Field-Weighted Citation Impact: 0.00